// App-Quantinova.ai

5505 : EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer.

Researchers

Presenter

  • Shannon Neville Westin

Principal Investigators

  • Bryan M. Fellman

  • Ying Yuan

  • Anil K. Sood

  • Pamela T. Soliman

  • Alexi A. Wright

  • Neil S. Horowitz

  • Susana M. Campos

  • Panagiotis A. Konstantinopoulos

  • Charles F. Levenback

  • David Marc Gershenson

  • Karen H. Lu

  • Virginia Bayer

  • Sobiya Tukdi

  • Alexis Rabbit

  • Lone Ottesen

  • Robert Godin

  • Gordon B. Mills

  • Joyce F. Liu

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • US Oncology Research, The Woodlands, TX

  • Dana-Farber Cancer Institute, Boston, MA

  • AstraZeneca, Waltham, MA

  • Oregon Health and Science University, Portland, OR

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Peritoneal cancer

  • Gynaecological cancer

Biomarkers

  • N/A

Drug/Treatment

  • MK1775

  • Olaparib

Outcome

  • N/A

Study Design

  • Randomized

  • Multiple Arm

  • Non-Comparative

Phase

  • II

Study Id's

  • NCT03579316

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved